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Abstract
Background: Physical inactivity increases the risk of atherosclerosis. However, the molecular
mechanisms of this relation are poorly understood. A recent report indicates that endostatin, an
endogenous angiostatic factor, inhibits the progression of atherosclerosis, and suggests that
reducing intimal and atherosclerotic plaque tissue neovascularization can inhibit the progression
atherosclerosis in animal models. We hypothesize that exercise can elevate the circulatory
endostatin level. Hence, exercise can protect against one of the mechanisms of atherosclerosis.
Results: We examined treadmill exercise tests in healthy volunteers to determine the effect of
exercise on plasma levels of endostatin and other angiogenic regulators. Oxygen consumption
(VO2) was calculated. Plasma levels of endostatin, vascular endothelial growth factor (VEGF), and
basic fibroblast growth factor (bFGF) were determined using ELISA. The total peak VO2 (L) in 7
male subjects was 29.5 ± 17.8 over a 4–10 minute interval of exercise. Basal plasma levels of
endostatin (immediately before exercise) were 20.3 ± 3.2 pg/ml, the plasma levels increased to 29.3
± 4.2, 35.2 ± 1.8, and 27.1 ± 2.2 ng/ml, at 0.5, 2, and 6 h, respectively, after exercise. There was a
strong linear correlation between increased plasma levels of endostatin (%) and the total peak VO2
(L) related to exercise (R2 = 0.9388; P < 0.01). Concurrently, VEGF levels decreased to 28.3 ± 6.4,
17.6 ± 2.4, and 26.5 ± 12.5 pg/ml, at 0.5, 2, and 6 h, respectively, after exercise. There were no
significant changes in plasma bFGF levels in those subjects before and after exercise.
Conclusions: The results suggest that circulating endostatin can be significantly increased by
exercise in proportion to the peak oxygen consumption under physiological conditions in healthy
volunteers. These findings may provide new insights into the molecular links between physical
inactivity and the risk of angiogenesis dependent diseases such as atherosclerosis.
Background
Epidemiological data has established that physical inac-
tivity increases the risk of many chronic diseases including
atherosclerosis [1-3]. Coronary heart disease, ischemic
stroke, and peripheral vascular disease are the clinical
manifestations of atherosclerosis. Physical inactivity is
believed to be an independent risk factor for the develop-
ment of coronary heart disease [4], stroke [5], and periph-
eral vascular disease [6]. However, exercise can exert a
beneficial influence on the risk factors for atherosclerosis
by reducing hyperlipidemia, hypertension, obesity, plate-
let aggregability; increasing insulin sensitivity; and
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improving glucose tolerance [7]. Despite these findings,
the molecular basis of interactions between body and
exercise in relation to atherosclerosis are poorly
understood.
Although atherosclerosis has complex and multifactorial
mechanisms, recent evidence also suggests that angiogen-
esis plays a critical role in the progression of atherogenesis
[8]. Angiogenesis, defined as the formation of new blood
vessels from an existing capillary bed, plays an important
role in wound healing, body development, and inflam-
mation, which also occurs in a variety of pathological
states. Progressive angiogenesis in a primary atheroscle-
rotic lesion has been considered as a cause of plaque
expansion, plaque vulnerability, and the risk of significant
disease complications such as plaque rupture and vascular
thrombosis [8-11]. Mounting evidence [12,13] suggests
that angiogenesis is regulated by a net balance between
positive (angiogenic) and negative (angiostatic) regula-
tors of blood vessel growth. A balance shifted towards pre-
dominantly positive regulators is an angiogenic-
phenotype, whereas, a shift favoring negative regulators is
an angiostatic-phenotype. Therefore, the impaired regula-
tion of angiogenesis is often associated with the develop-
ment of angiogenesis-dependent diseases such as
atherosclerosis. We hypothesize that exercise can increase
endostatin (an angiostatic factor) in circulation, and
thereby, it may be one of the mechanisms by which exer-
cise can protect against atherosclerosis.
Why is endostatin thought to be an important molecule
linked to angiogenesis-dependent diseases such as athero-
sclerosis? Endostatin is an endogenous angiostatic factor
(inhibitor of angiogenesis) identified originally in condi-
tioned media of Murine hemangioendothelioma cells
[13,14]. In mice, recombinant endostatin decreased the
size of established primary and secondary tumors, and
repetitive application of the peptide prevented recurrence
of the tumors by inhibiting tumor angiogenesis [12].
Recent evidence has indicated that endostatin can inhibit
the progression of atherosclerosis in an ApoE-deficient
mouse model by reducing intimal and plaque tissue neo-
vascularization [15].
The present study seeks to determine: 1) whether exercise
can increase plasma levels of endostatin in healthy volun-
teers; 2) whether increased plasma levels of endostatin are
correlated with the intensity of exercise assessed by the
peak oxygen consumption; and 3) whether exercise can
affect plasma levels of angiogenic factors, such as VEGF
and bFGF.
Results
General Characteristics and Response to Exercise
7 healthy-male-volunteers were assigned to the treadmill-
exercise study (years of age, 33 ± 13; body weight [kg] 78
± 13; mean ± SD). The peak speed and the time spent at
peak speed on the treadmill were 4.85 ± 0.99 miles per
hour and 6.86 ± 2.67 minutes (ranging 4 to 10 minutes),
respectively. The total duration of treadmill-exercise
lasted an average of 18.86 ± 6.96 minutes. At peak speed,
the heart rate was significantly increased by 87% (P <
0.01) from 80 ± 8 beats/min (resting heart rate) to 167 ±
9 beats/min (peak heart rate). Neither abnormal ECG
signs nor abnormal symptoms were observed during or
after exercise.
Effect of Exercise on Oxygen Consumption
In this study, termination of exercise was based on the
attainment of 80–93% of the maximal predicted heart
rate and the tolerance of each individual. Therefore, these
conditions caused differences in peak oxygen consump-
tion for each volunteer. Using the mathematical equation
[16], the estimated peak oxygen consumption (peak VO2;
L/min) was 4.06 ± 1.08 (mean ± SD; n = 7), and ranged
from 2.67 to 5.88. The peak oxygen pulse (peak O2 pulse,
ml/beat), calculated by dividing peak VO2 by heart rate,
was 24.36 ± 6.77, and ranged from 16.18 to 37.45. Regres-
sion analysis shows a strong linear correlation between
peak O2 pulse and peak VO2 in different individuals (R =
0.9571; R2 = 0.9505; P < 0.01). The total peak VO2 (L),
considered as the product of peak VO2 and the time spent
running at that peak, was 29.5 ± 17.8, and ranged from
12.7 to 58.8.
Effect of Exercise on Plasma Levels of Endostatin
Figure 1 shows that exercise increased plasma levels of
endostatin in healthy volunteers. Basal plasma levels of
endostatin (immediately before exercise) were 20.3 ± 3.2
ng/ml (mean ± SE; n = 7). The plasma levels increased to
29.1 ± 4.2, 35.2 ± 1.8, and 27.1 ± 2.2 ng/ml, respectively,
at 0.5, 2, and 6 h after treadmill exercise. The percent
increases in plasma endostatin concentrations were 43%
(P = 0.014), 73% (P = 0.004), and 33% (P = 0.034) at 0.5
h, 2 h, and 6 h after exercise, respectively, compared to the
pre-exercise levels. Figure 2 shows a strong linear correla-
tion between % increase in plasma levels of endostatin
and the total peak VO2 (R = 0.969; R2 = 0.9388; P < 0.01).
Effect of Exercise on Plasma Levels of VEGF and bFGF
We also investigated the effect of exercise on plasma levels
of VEGF and bFGF. We found that acute treadmill-exercise
causes a decrease in plasma levels of VEGF in healthy vol-
unteers. These changes are statistically significant at 2 h
after exercise compared to the basal levels immediately
before exercise (P = 0.0347; n = 7). Basal plasma levels of
VEGF were 37.4 ± 7.8 pg/ml (mean ± SE). Plasma VEGFBMC Physiology 2004, 4 http://www.biomedcentral.com/1472-6793/4/2
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levels decreased to 28.3± 6.4, 17.6 ± 2.4, and 26.5 ± 12.5
pg/ml, respectively, at 0.5, 2, and 6 h after treadmill-exer-
cise. These values reflect percent changes of 24% (P =
0.159), 53% (P = 0.035), and 29% (P = 0.182) at 0.5 h, 2
h, and 6 h after exercise, respectively, compared to the
basal plasma levels. The regression analysis also indicated
a good linear correlation between % decrease in plasma
levels of VEGF and the total peak VO2 (R = 0.6410). Basal
levels of plasma bFGF (immediately before exercise) were
detected in only 4 of 7 subjects using an assay (R&D, cat-
alog number DFB50). The plasma levels of bFGF in those
4 subjects averaged 6.3 ± 0.5 and 6.8 ± 0.8 pg/ml, respec-
tively, before and 2 h after exercise (P = 0.483).
Correlation between Plasma Endostatin and VEGF Levels
Interestingly, regression analysis indicated a significant
negative correlation between basal plasma endostatin and
VEGF levels among the 7 male volunteers (R = 0.7235; R2
= 0.8510; P = 0.015), in which a higher endostatin level is
associated with a lower VEGF level. A good linear correla-
tion between % increase in endostatin and % decrease in
VEGF levels was also found 2 h after exercise (R = 0.6541;
P = 0.0811). These findings were consistent with the pos-
sibility that exercise may induce an angiostatic-phenotype
(induction of endostatin and reduction of VEGF) in circu-
lation of humans.
Discussion
The present study indicates that detectable amounts of
endostatin are present in the plasma of healthy subjects.
Basal plasma endostatin levels were 20.3 ± 3.2 ng/ml
(ranging 10.3 to 29.6 ng/ml in males). These results are
consistent with other reports using a similar assay in
which median serum endostatin levels were 13.8 ng/ml
(ranging 11.1 to 15.4 ng/ml) in healthy male subjects
[17]. The circulating form of human endostatin has also
been detected by other methods such as Western blot [17]
and mass spectrometry [18]. These basal levels of endosta-
tin may be generated as a by-product of physiological col-
lagen turnover. The presence of endostatin in the
circulation of healthy subjects suggests that angiostatic
factors may play an important role in the homeostatic reg-
ulation of angiogenesis under a normal condition [13].
Feldman et al [17] using the same endostatin assay
(Cytimmune Sciences Inc.; College Park, MD) showed
that the immunoreactivity of endostatin detected in nor-
mal human serum and plasma is essentially identical to
that of recombinant endostatin. However, the functional
status of circulating endogenous endostatin in humans
remains unclear. Further studies are needed to determine
whether circulating endogenous endostatin or what levels
of endostatin can have a physiological function.
Changes in plasma levels of endostatin before and after exer- cise at different time point in 7 healthy adults Figure 1
Changes in plasma levels of endostatin before and after exer-
cise at different time point in 7 healthy adults. The plasma 
endostatin concentrations were increased by 43% (*P = 
0.0136), 73% (*P = 0.004), and 33% (P = 0.034) at 0.5 h, 2 h, 
and 6 h after exercise, respectively, compared to the pre-
exercise levels (20.3 ± 3.2 ng/ml, mean ± SE).
Oxygen consumption (VO2) during treadmill-exercise in rela- tion to % increased plasma endostatin Figure 2
Oxygen consumption (VO2) during treadmill-exercise in rela-
tion to % increased plasma endostatin. The peak speed and 
the time spent at peak speed on the treadmill were 4.85 ± 
0.99 (mean ± SD) miles per hour and 6.86 ± 2.76 minutes (n 
= 7; ranging 4–10 min), respectively. The total peak VO2 was 
considered as the product of peak VO2 and the time spent 
running at that peak. The % increased plasma endostatin after 
exercise ranged from 30% to 300% for different individual. 
There was a strong linear correlation between % increase in 
plasma levels of endostatin and the total peak VO2 (R = 
0.969; R2 = 0.9388; P < 0.01).
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To our knowledge, the present study is the first to demon-
strate that circulating endostatin can be significantly
increased by exercise in proportion to the peak oxygen
consumption under physiological conditions. Although
the mechanism of endostatin release remains unclear,
many studies have shown that the proteolytic release of
endostatin from collagen XVIII is mediated by proteases
of many classes, such as cysteine proteases, matrix metal-
loproteases, and aspartic proteases [19,20]. Many of these
proteases are associated with physiological collagen turn-
over that could be enhanced by physical exercise [21,22].
Therefore, we can speculate that exercise-induced
endostatin release is associated with a higher collagen
turnover rate.
Another mechanism of endostatin release may involve
activation and release of extracellular matrix proteases
associated with the angiogenic process. Many in vivo stud-
ies have demonstrated that exercise induces angiogenesis
in cardiac [23] and skeletal muscles [24]. It is therefore
conceivable that these proteases are also responsible for
releasing endogenous angiostatic factors such as endosta-
tin. Furthermore, exercise may alter the binding character-
istics of endostatin in metabolically active tissues and may
increase blood flow to these tissues. These conditions may
wash endostatin into the general circulation. Our prelim-
inary data suggest that 3 weeks of exercise-training can sig-
nificantly decrease endostatin levels in rat tibialis anterior
muscle and increase circulating endostatin levels (unpub-
lished observations). This latter finding supports our
hypothesis that exercise-induced circulating endostatin
may be derived primarily from skeletal and cardiac mus-
cles. However, further studies are needed to investigate
mechanisms of exercise-induced endostatin release.
It is well-known that angiogenesis is often a compensa-
tory response to a prolonged imbalance between the met-
abolic requirements of the tissues and the perfusion
capabilities of the vasculature [25]. Alteration in the
expression of angiogenic factors, such as VEGF and bFGF,
in tissues or circulation of the subjects following exercise,
has been observed in animals [24,26] and humans [27-
31]. Several human studies [27,29] have shown that exer-
cise causes a transient decrease in circulating VEGF levels,
while exercise increases VEGF expression in human skele-
tal muscle [30,31]. The present study confirms these pre-
vious reports and further shows that the transient decrease
in circulating VEGF levels caused by exercise in healthy
volunteers is proportional to the total peak oxygen con-
sumption. The transient decrease in circulating VEGF lev-
els caused by exercise in healthy adults does not
necessarily mean that exercise can cause down-regulation
of VEGF in the local muscle [29,30].
The mechanism responsible for the transient decrease in
circulating VEGF caused by exercise is poorly understood.
However, possible explanations might be as follows: 1)
increased VEGF binding-affinity to its receptors at the
endothelium, which would stimulate angiogenesis in the
local tissues such as heart and skeletal muscles, and 2) a
substantial increase in circulating VEGF binding proteins,
which would protect the vascular system from a deleteri-
ous increase in VEGF-induced hyperpermeability [29,32].
In the present study, we have found that acute exercise
caused a significant increase in circulating endostatin lev-
els. Moreover, the highest induction of endostatin in cir-
culation after treadmill exercises was observed in a subject
who was a triathlon athlete and performed the greatest
intensity of exercise. In addition, as mentioned above, our
preliminary data suggest that 3 weeks of exercise-training
can significantly decrease endostatin levels in the rat tibi-
alis anterior muscle and increase circulation endostatin
levels. Therefore, it is likely that exercise can increase
endostatin in circulation acutely as well as chronically.
However, further studies are needed for evaluating the
long-term effect of exercise on increasing circulatory
endostatin levels.
Angiogenesis appears to have both beneficial and delete-
rious effects in atherosclerosis. Whereas increased angio-
genesis in the heart tissue may be a favorable sign in the
healing of the ischemic tissues [35], progressive angiogen-
esis in a primary atherosclerotic lesion could be a cause of
plaque expansion [33,34]. Our previous studies [24] as
well as those from other laboratories have shown that
exercise induces a local angiogenic phenotype character-
ized by over-expression of VEGF in skeletal muscle [27,29-
31] and heart [35]. This local induction of an angiogenic
phenotype by exercise appears to stimulate angiogenesis
and thereby prevent ischemia in these tissues. As men-
tioned before, endostatin is an endogenous angiostatic
factor that can inhibit the progression of atherosclerosis in
a ApoE-deficient mouse model by reducing intimal and
plaque tissue neovascularization [15]. Therefore, exercise
can also exert a beneficial effect against atherosclerosis by
increasing circulating endostatin that may inhibit devel-
opment of atherosclerotic plaque through blocking angio-
genesis in the plaque tissue.
Conclusions
In conclusion, the present study shows that detectable
amounts of endostatin are present in the plasma of
healthy subjects and that circulating endostatin levels can
be significantly increased by exercise. The magnitude of
increased circulating endostatin appears to be propor-
tional to the severity of exercise as assessed by total peak
oxygen consumption. In the present study, exercise caused
a transient decrease in circulating VEGF levels and did notBMC Physiology 2004, 4 http://www.biomedcentral.com/1472-6793/4/2
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change plasma bFGF levels. These findings may provide
new insights into the molecular links between physical-
inactivity and the risk of angiogenesis-dependent diseases
such as atherosclerosis.
Methods
Selection of Subjects
Seven healthy-male research personnel at University Mis-
sissippi Medical Center (UMMC) participated in the study
(ages ranging from 18–49 years). The subjects were
selected based on the absence of a history of malignancy,
coronary heart disease, peripheral vascular disease, and
hypertension. All subjects had different physical activity
backgrounds including one who was a triathlon athlete
and an individual who did little leisure-time physical
activity. In addition, all subjects were non-smokers and
abstained from alcohol consumption for 24 hours prior
to the study. Informed consent was obtained from all sub-
jects. The study protocol was approved by the Institu-
tional Review Board of UMMC.
Exercise Study Protocol
The exercise was performed on a treadmill according to a
modified Ellestad Protocol [16]. Briefly, each individual
started the treadmill exercise at a speed of 2–3 mph at a
fixed grade of 15%. The speed was increased in stages of
0.5–1.0 mph to a peak speed of 4.0–6.5 mile per hour
(mph), each stage taking 1–3 min. Each individual ran on
the treadmill at peak speed for 4–10 minutes. The subjects
were monitored by ECG during the exercise. Termination
of exercise was based on attainment of 80–93% of maxi-
mal predicted heart rate and the tolerance of each individ-
ual. All volunteers did not have any food consumption
until 6 h after exercise.
Measurement of Plasma Levels of Endostatin, VEGF, and 
bFGF
Three-ml of blood were collected by venipuncture-tube
with EDTA solution immediately before and 0.5 h, 2 h,
and 6 h after exercise. The blood samples were immedi-
ately centrifuged at 700 × g in a micro-centrifuge for 5
minutes at 4°C; and the plasma was stored at -70°C.
Plasma levels of endostatin (ng/ml) were measured using
human endostatin ELISA kits (Cytimmune Sciences Inc.;
College Park, MD) according to manufacturer protocol.
Plasma levels of VEGF or bFGF were determined using
human ELISA kits (R&D Systems, Minneapolis, MN).
Estimation of Oxygen Consumption
Oxygen consumption (VO2) was estimated by the follow-
ing equation [16]: VO2 = V × W × (0.073 +OC/100) × 1.8
(VO2 = oxygen consumption in ml/min [standard temper-
ature and pressure dry]; V = treadmill speed in m/min; W
= body weight in kg; OC = treadmill angle in percent; 1.8
= factor constituting the oxygen requirement in ml/min
for 1 m/kg of work). This equation is applicable to a tread-
mill program, which gives a rough estimate of oxygen
consumption at any speed and grade. In addition, this
mathematical estimation provides values of oxygen con-
sumption similar to those obtained from direct
measurements when using treadmill exercise protocol
[16]. The peak VO2 (L/min) was estimated by calculation
of VO2 when the individual exercised at peak speed. The
total peak VO2 (L) was considered as the product of peak
VO2 and the time spent running at the peak level. The
peak oxygen pulse (ml O2/beat) was calculated as the
quotient of peak VO2 (L/min) and peak heart rate (beats/
min) during exercise.
Statistical Analysis
Where indicated, data is presented as mean ± SE. Statisti-
cal significance was defined as a two-tail Student's t-test
value of P < 0.05. Paired Student's t-test was used to com-
pare variables between two groups (before and during or
after exercise). Linear-regression was performed to assess
the relationships between two continuous variables. All
statistical calculations were performed with SigmaStat
software (Jandel Corporation, San Rafael, CA).
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